A new blood test for advanced prostate cancer
Validation of predictive liquid biomarkers for patients with metastatic prostate cancer
This project aims to develop a new blood test to help doctors quickly identify when prostate cancer is becoming resistant to treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11087719 on NIH RePORTER |
What this research studies
Many men with advanced prostate cancer benefit from initial treatments, but their cancer often becomes resistant over time, which can lead to delays in finding the right next treatment. Our goal is to create a simple blood test that looks for specific signs in circulating tumor cells. This test could help doctors understand sooner if your cancer is changing, allowing them to adjust your treatment plan more quickly. The hope is to improve how we manage prostate cancer that has become resistant to standard therapies.
Who could benefit from this research
Good fit: This research is for patients with metastatic prostate cancer, especially those whose cancer has become resistant to initial hormone-blocking treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet received treatment for advanced disease may not directly benefit from this specific biomarker test.
Why it matters
Potential benefit: If successful, this new blood test could help patients with advanced prostate cancer receive more effective treatments sooner, potentially improving their survival and quality of life.
How similar studies have performed: While the concept of liquid biopsies is gaining traction, this specific biomarker assay for treatment-resistant prostate cancer is undergoing rigorous validation to establish its clinical utility.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Lang, Joshua — University of Wisconsin-Madison
- Study coordinator: Lang, Joshua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.